452 results on '"Wörns, Marcus A."'
Search Results
152. Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
153. Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center “real-life” cohort
154. The transcription factor Bcl-3 regulates the development of marginal zone, germinal center and B1 B cells (LYM7P.624)
155. Predictive Scores in Primary Biliary Cirrhosis
156. Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma
157. Leberzirrhose und hepatorenales Syndrom: Das Ansprechen auf Terlipressin und Albumin ist mit besserem Überleben assoziiert
158. Randomized Comparison of Selective Internal Radiotherapy (SIRT) Versus Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE) for the Treatment of Hepatocellular Carcinoma
159. Survival analysis of proposed BCLC-B subgroups in hepatocellular carcinoma patients
160. Sa1498 - Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir in Adults with Chronic Genotype 1-6 Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis
161. Epidemiology of hepatic encephalopathy in german hospitals - the EpHE study.
162. Combination therapy with silibinin, pegylated interferon and ribavirin in a patient with hepatitis C virus genotype 3 reinfection after liver transplantation: a case report
163. Sorafenib for the treatment of hepatocellular carcinoma
164. Trends in Epidemiology, Treatment, and Survival of Hepatocellular Carcinoma Patients Between 1998 and 2009
165. HCC therapies—lessons learned
166. Overexpression of Bcl‐3 inhibits the development of marginal zone B cells
167. The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib
168. Systemic Therapy and Synergies by Combination
169. Early changes in dynamic biomarkers of liver fibrosis in hepatitis C virus-infected patients treated with sofosbuvir.
170. Liver specific deletion of CYLDexon7/8 induces severe biliary damage, fibrosis and increases hepatocarcinogenesis in mice
171. Clinicopathologic Features and Prognosis of Young Patients With Hepatocellular Carcinoma in a Large German Cohort
172. P-0082 Dose Escalation of the HDAC Inhibitor Resminostat in Combination Treatment with Sorafenib in Patients with Hepatocellular Carcinoma
173. Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation
174. Prognostic factors and outcomes of patients with hepatocellular carcinoma in non-cirrhotic liver
175. Ablation of c-FLIP in hepatocytes enhances death-receptor mediated apoptosis and toxic liver injury in vivo
176. T cell specific overexpression of Bcl-3 impairs T cell activation and causes severe colonic inflammation (148.17)
177. Future perspectives in hepatocellular carcinoma
178. Novel inhibitors in development for hepatocellular carcinoma
179. Concurrent Autoimmune Diseases in Patients With Autoimmune Hepatitis
180. Sunitinib in Patients with Advanced Hepatocellular Carcinoma after Progression under Sorafenib Treatment
181. Safety and Efficacy of Sorafenib in Patients With Advanced Hepatocellular Carcinoma in Consideration of Concomitant Stage of Liver Cirrhosis
182. Systemic Therapies in Hepatocellular Carcinoma
183. Regulation of B cell homeostasis and activation by the tumor suppressor gene CYLD
184. Efficacy of an escalating dose regimen of pegylated interferon ?-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation
185. Hereditäre Lebererkrankungen
186. Randomized Comparison of Selective Internal Radiotherapy (SIRT) Versus Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE) for the Treatment of Hepatocellular Carcinoma.
187. Five Cases ofDe NovoInflammatory Bowel Disease After Orthotopic Liver Transplantation
188. Triple antiviral therapy with telaprevir after liver transplantation: a case series.
189. Overexpression of Bcl-3 inhibits the development of marginal zone B cells.
190. Hepatocellular carcinoma in 2017: Two large steps forward, one small step back
191. Characteristics of bacterial infections and prevalence of multidrug-resistant bacteria in hospitalized patients with liver cirrhosis in Germany
192. Increased hepatic fibrosis and JNK2-dependent liver injury in mice exhibiting hepatocyte-specific deletion of cFLIP.
193. Validation of EncephalApp_Stroop as screening tool for the detection of minimal hepatic encephalopathy in German patients with liver cirrhosis
194. Impact of acute-on-chronic liver failure and decompensated liver cirrhosis on psychosocial burden and quality of life of patients and their close relatives.
195. Comparison of Inflammatory Cytokine Levels in Hepatic and Jugular Veins of Patients with Cirrhosis.
196. Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients.
197. Health literacy in gastrointestinal diseases: a comparative analysis between patients with liver cirrhosis, inflammatory bowel disease and gastrointestinal cancer.
198. Management of Hepatic Sarcoidosis.
199. Structured Early detection of Asymptomatic Liver Cirrhosis: Results of the population-based liver screening program SEAL.
200. Liver Frailty Index for Prediction of Short-Term Rehospitalization in Patients with Liver Cirrhosis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.